Kymera Therapeutics Inc (KYMR) News

Form 8-K - Current report

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the...

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the...

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...